HOME >> BIOLOGY >> NEWS
Nervous inhibitions

If inhibitory neurons are prevented from carrying out their function, this causes major defects early in embryonal development - and these defects can even occur outside the nervous system. These are the results of a study recently published by scientists from the Max Planck Institute for Experimental Medicine in Göttingen (Neuron, May 18, 2006).

The most common inhibitory transmitters in the mammalian central nervous system are GABA and glycine. Nerve cells can release GABA or glycine where they contact other nerve cells at junctions called synapses. This typically prevents further signal transmission by the post-synaptic cell.

Most inhibitory nerve cells release either GABA or glycine. However, some inhibitory nerve cells appear to be "bilingual", releasing a mixture of GABA and glycine. These mixed-release cells are most common during nervous system development and seem to be crucial for normal spinal cord growth. For brain researchers, however, they have proven mysterious. Most nerve cells specialise in releasing only one type of neurotransmitter. They use transport proteins to pump the neurotransmitter into vesicles surrounded by a membrane and store it there until release is triggered.

Sonja Wojcik and Jeong-Seop Rhee, from the Department of Molecular Neurobiology at the Max Planck Institute for Experimental Medicine in Göttingen, Germany, working with colleagues from Kaiserslautern, Germany and Houston, Texas, have discovered what enables nerve cells to release both GABA and glycine. The researchers discovered that one particular transport protein called VIAAT is able to store both GABA and glycine in vesicles; this joint storage is rather unusual for a classical neurotransmitter. The scientists genetically altered mice so that their nerve cells do not produce VIAAT. This change eliminated both GABA and glycine release.

The scientists did not just solve the problem of simultaneous release of GABA and glycine from "bilingual" sp
'"/>

Contact: Dr. Sonja M. Wojcik
wojcik@em.mpg.de
49-551-389-9722
Max-Planck-Gesellschaft
29-May-2006


Page: 1 2

Related biology news :

1. Cooperative science program yields results
2. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
3. Smelling for first time results from knowing abnormalities in congenital loss of smell
4. BDSI announces positive phase III clinical trial results
5. Scientists meet to review Envisat results after 5 years of operations
6. Environment and exercise may affect research results, UA study shows
7. Preliminary results of largest scan of autism DNA information
8. Human trial results show excellent safety data, from Geovaxs DNA/MVA AIDS vaccines
9. Rodent sperm work together for better results
10. Dramatic results from combo therapy surprises Krabb-disease researchers
11. TIGER workshop highlights project results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to ... a near term focus on Type 2 diabetes and associated comorbidities. , Justin ... therapeutic areas and classes. As Chief Commercial Officer, Justin will lead Better ...
(Date:7/18/2020)... ... 2020 , ... Commercial launch readiness is a critical stage in a product ... or vaccine, the global economic downturn will only increase price pressures overall for the ... capturing full value from every product launch is critical. However, history shows that only ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... (PRWEB) , ... August 11, 2020 , ... ... a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network ... 2021 and 2022. The network is a consortium of academic research centers in ...
(Date:8/7/2020)... (PRWEB) , ... August 06, 2020 , ... ... DNA vaccine industries, announces it has closed on the purchase of greenfield for ... in Conroe, TX and includes over 21 acres in the initial acquisition, with ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products has ... different materials for use with CRM, neurostimulation, vascular, and related devices. , ... specific design requirements, performance, and cost criteria; especially where solid wire is limited. ...
Breaking Biology Technology:
Cached News: